Literature DB >> 20514076

β-Arrestin2 influences the response to methadone in opioid-dependent patients.

B Oneda1, S Crettol, M Bochud, J Besson, M Croquette-Krokar, R Hämmig, M Monnat, M Preisig, C B Eap.   

Abstract

β-Arrestin2 (ARRB2) is a component of the G-protein-coupled receptor complex and is involved in μ-opioid and dopamine D(2) receptor signaling, two central processes in methadone signal transduction. We analyzed 238 patients in methadone maintenance treatment (MMT) and identified a haplotype block (rs34230287, rs3786047, rs1045280 and rs2036657) spanning almost the entire ARRB2 locus. Although none of these single nucleotide polymorphisms (SNPs) leads to a change in amino-acid sequence, we found that for all the SNPs analyzed, with exception of rs34230287, homozygosity for the variant allele confers a nonresponding phenotype (n=73; rs1045280C and rs2036657G: OR=3.1, 95% CI=1.5-6.3, P=0.004; rs3786047A: OR=2.5, 95% CI=1.2-5.1, P=0.02) also illustrated by a 12-fold shorter period of negative urine screening (P=0.01). The ARRB2 genotype may thus contribute to the interindividual variability in the response to MMT and help to predict response to treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514076     DOI: 10.1038/tpj.2010.37

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  18 in total

1.  β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.

Authors:  Lauren M Slosky; Yushi Bai; Krisztian Toth; Caroline Ray; Lauren K Rochelle; Alexandra Badea; Rahul Chandrasekhar; Vladimir M Pogorelov; Dennis M Abraham; Namratha Atluri; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick Maloney; Hong Yuan; Zibo Li; William C Wetsel; Anthony B Pinkerton; Lawrence S Barak; Marc G Caron
Journal:  Cell       Date:  2020-05-28       Impact factor: 41.582

Review 2.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

3.  Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Xu Shu; Jurg Ott; Pei-Hong Shen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

4.  Association study of the β-arrestin 2 gene (ARRB2) with opioid and cocaine dependence in a European-American population.

Authors:  Lisa M Ambrose-Lanci; Meera Vaswani; Toni-Kim Clarke; Angela Zeng; Falk W Lohoff; Thomas N Ferraro; Wade H Berrettini
Journal:  Psychiatr Genet       Date:  2012-06       Impact factor: 2.458

Review 5.  Arrestin mutations: Some cause diseases, others promise cure.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Prog Mol Biol Transl Sci       Date:  2018-10-24       Impact factor: 3.622

Review 6.  Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Authors:  Mary Jeanne Kreek; Orna Levran; Brian Reed; Stefan D Schlussman; Yan Zhou; Eduardo R Butelman
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 7.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

8.  Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.

Authors:  Caroline Victorri-Vigneau; Céline Verstuyft; Régis Bouquié; Edouard-Jules Laforgue; Jean-Benoit Hardouin; Juliette Leboucher; Bertrand Le Geay; Corine Dano; Gaëlle Challet-Bouju; Marie Grall-Bronnec
Journal:  Br J Clin Pharmacol       Date:  2019-05-11       Impact factor: 4.335

9.  An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors:  Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

10.  Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.

Authors:  Richard C Crist; James Li; Glenn A Doyle; Alex Gilbert; Bryan M Dechairo; Wade H Berrettini
Journal:  Am J Drug Alcohol Abuse       Date:  2018-01-15       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.